What ARCHIMED does

ARCHIMED is a global private equity firm founded in 2014 by former 3i Healthcare leaders and headquartered in Lyon, France, with additional offices in New York, Tokyo, and Singapore. It is Europe's first independent PE fund dedicated exclusively to the healthcare sector, managing approximately €9-11 billion in assets under management across a series of specialized vehicles including MED I, MED II, MED Platform I, MED Platform II, MED Rise, MED III, MED Bio, MED Vet, and MED Access. The firm invests across seven healthcare sub-sectors — Diagnostics, MedTech, Biopharma Products, Consumer Health, Healthcare IT, Life Science Tools & Services, and Animal & Environmental Health — targeting small-cap growth, mid-market buy-and-build, and large-cap buyout opportunities globally.

The firm operates with 160+ professionals split evenly across finance, scientific, and operational expertise, supported by proprietary tools including the MedSeg sector analysis platform (covering 430 healthcare sub-segments), the MedDiscover sourcing toolkit, and the MedValue value-creation framework, which drives portfolio company growth through internationalization, innovation, and bolt-on acquisitions. ARCHIMED's model is classic institutional PE: it raises capital from limited partners including endowments, foundations, family offices, banks, insurers, and sovereign wealth funds, and generates revenue through management fees on committed capital (typically ~1.5-2% of AUM) and carried interest on successful exits above the hurdle rate. Notable recent transactions include the Stago acquisition alongside CDPQ (2026, €550M revenue target), the announced $1.1B take-private of Esperion Therapeutics (2026), the $730M acquisition of ZimVie (2025), the $1.1B take-private of Natus Medical (2022), and successful exits including Polyplus (300x return to MED I), DIESSE (4.6x), Vita Health (4.5x), and Ad-Tech (5x via joint venture with Nihon Kohden). All ARCHIMED Buyout funds are classified as top-quartile performers, and the firm was ranked 11th of 695 PE firms globally in the Dow Jones-HEC Performance Ranking.

Name

ARCHIMED

Legal name

ARCHIMED SAS

Website

https://archimed.group

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

51–100 employees

Short description

ARCHIMED is a global healthcare-exclusive private equity firm founded in 2014, managing approximately €9-11 billion across multiple fund vehicles and serving healthcare companies worldwide with growth capital, operational expertise, and internationalization support through a team of 160+ professionals.

Ownership category

akta.pro rank

Product category

Healthcare Private Equity Investment Management

NAICS

Funds, Trusts, and Other Financial Vehicles (525), Other Investment Pools and Funds (5259)

SIC

Investment Advice (6282)

akta.pro primary industry

Healthcare Access & Life Sciences Impact Funds (FSANAJAI)

akta.pro secondary industry

Specialized/Niche-Vertical RIAs (e.g., Medical, Tech, Executives, Athletes) (FSAAACAL)

Keywords

• Healthcare private equity
• Medical growth capital
• Healthcare buyout funds
• Healthcare investment management
• Medtech and biopharma investing

Headquarters

HQ city

Lyon

HQ country

France

HQ region

Europe

Offices4 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales

Revenue model

1. Management Fees: ARCHIMED generates management fees from its funds based on committed capital under management. These fees provide recurring revenue to support operations.
2. Carried Interest: Performance-based carried interest earned when portfolio companies achieve successful exits above the hurdle rate. This aligns fund manager and investor interests and is the primary driver of fund manager returns.
3. Investment Returns: Returns from equity stakes in portfolio companies, realized through exits and strategic transactions.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

ARCHIMED is a healthcare-only private equity firm that raises and deploys capital through multiple specialized fund vehicles (MED I, MED II, MED Platform I, MED Platform II, MED Rise, MED III) targeting small-cap, mid-market, and large-cap healthcare companies. The firm provides portfolio companies with long-term capital, operational/medical/scientific expertise, internationalization support, acquisition capabilities, and innovation enablement. Aggregate assets under management stand at approximately €9–11 billion, deployed across seven healthcare sub-sectors including Animal & Environmental Health, Biopharma Products, Consumer Health, Diagnostics, Healthcare IT, Life Science Tools & Services, and MedTech.

Product overview

ARCHIMED is a healthcare-focused private equity investment firm offering multiple specialized fund vehicles (MED I, MED II, MED Platform I, MED Platform II, MED Rise, MED III, MED Access, MED Bio, MED Vet) that manage €8-11 billion in aggregate capital. The funds target different segments of the healthcare industry including small-cap growth, mid-market buy-and-build, and sector-specific strategies. ARCHIMED provides strategic and financial partnership to healthcare businesses through its proprietary MedValue value creation framework and MedSeg sector analysis tools, helping portfolio companies internationalize, acquire, innovate and expand. Prioritized investment areas include Animal & Environmental Health, Biopharma Products, Consumer Health, Diagnostics, Healthcare IT, Life Science Tools & Services, and MedTech.

Differentiator

Problem solved

Functional benefit

Products and services

• MED Platform II ARCHIMED's mid-market buy-and-build fund targeting healthcare companies with approximately €3.5 billion in capital, focused on internationalization, innovation, and product range expansion across healthcare sub-sectors. For institutional LPs and healthcare companies seeking growth capital.
• MED Rise ARCHIMED's small-cap healthcare growth buyout fund that closed on its €400 million hardcap in April 2024, investing in early-stage healthcare companies including Rivadis, Arkstone, SeqCenter, FIM Medical, and IRAB. For institutional LPs and emerging healthcare companies.
• MED Platform I ARCHIMED's mid-market buy-and-build fund with approximately €800 million target size, focused on healthcare platform acquisitions across Europe and North America. For institutional LPs and mid-market healthcare companies.
• MED I ARCHIMED's inaugural healthcare-focused private equity fund that generated approximately 400% internal rate of return on its first exit and was ranked as the best buyout fund globally for its 2014 vintage. For institutional LPs.
• MED II ARCHIMED's second healthcare-focused fund that raised €315 million and invests in medtech, biopharma, care services and preventative healthcare sectors, with investments ranging from €5 million to €50 million per transaction. For institutional LPs and small/mid-market healthcare companies.
• MED III ARCHIMED's investment fund focused on healthcare industries, contributing to relevant United Nations Sustainable Development Goals and the firm's Health Objectives framework. For institutional LPs and healthcare companies.
• MED Access ARCHIMED fund focusing on healthcare access and services across various therapeutic areas. For institutional LPs and healthcare services companies.
• MED Bio ARCHIMED fund targeting biotechnology and biological services companies within the healthcare sector. For institutional LPs and biotech companies.
• MED Vet ARCHIMED fund focused on animal health investments within the healthcare industries. For institutional LPs and animal health companies.
• Healthcare Investment Management Services ARCHIMED provides strategic and financial partnership to healthcare businesses, helping partners internationalize, acquire, innovate and expand their products and services. The firm offers operational, medical, scientific and financial expertise across seven healthcare sectors. For portfolio companies and healthcare entrepreneurs.
• MedValue Value Creation Framework ARCHIMED's proprietary playbook for accelerating portfolio company growth via internationalization, innovation and product range expansion, including bolt-on acquisitions. For portfolio companies.

Quantifiable outcome

• All ARCHIMED Buyout funds are top quartile performers
• +1 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

One partnership is on record.

• Nihon KohdencoreStrategic or Co-development PartnerARCHIMED established a joint venture with Nihon Kohden for Ad-Tech growth in the healthcare sector. This represents a strategic partnership combining ARCHIMED's private equity capabilities with Nihon Kohden's healthcare technology expertise.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Permira (Healthcare): Permira's healthcare team focuses on MedTech, pharmaceuticals, and consumer health across Europe and globally. Comparable to ARCHIMED in deal size, sector specialization, and value-creation orientation through operational improvement and buy-and-build strategies.
• Avista Capital Partners: Avista is a healthcare-dedicated middle-market PE firm investing in pharma, MedTech, and healthcare services. Closely comparable to ARCHIMED given its healthcare-only thesis, mid-market deal sizes, and active operational support model.
• Welsh, Carson, Anderson & Stowe (Healthcare): WCAS is a healthcare-focused PE firm investing across healthcare services, pharma, and MedTech. Comparable to ARCHIMED in vertical specialization, US footprint, and active operational engagement with portfolio companies.
• EQT (Healthcare): EQT's healthcare team invests across MedTech, pharma services, and care providers in Europe and globally. Comparable to ARCHIMED in its European roots, sector specialization, and cross-border deal-making in healthcare subsectors like diagnostics and life sciences.
• GTCR (Healthcare): GTCR is a US-focused middle-market PE firm with deep healthcare specialization across healthcare services, MedTech, and pharma services. Comparable in sector focus, mid-market orientation, and Leaders Strategy approach to backing healthcare executives.
• Bain Capital Private Equity (Healthcare/Life Sciences): Bain Capital operates a large dedicated healthcare and life sciences vertical within its private equity platform, investing across biopharma, MedTech, diagnostics, and healthcare services globally. Directly comparable to ARCHIMED given focus on healthcare-only investing at scale and similar mid-to-large-cap deal sizes.

Broad incumbents

• KKR (Healthcare Strategic Growth): KKR's Healthcare Strategic Growth fund and broader healthcare practice invest across pharmaceuticals, MedTech, and healthcare services. While KKR is a generalist mega-fund, its dedicated healthcare arm competes directly with ARCHIMED for healthcare buyouts and growth equity globally.
• Carlyle (Global Healthcare): Carlyle's Global Healthcare team invests in biopharma, MedTech, and healthcare services. As a major generalist PE platform with a dedicated healthcare vertical, Carlyle competes with ARCHIMED for mid-to-large healthcare deals and similar LP relationships.
• CVC Capital Partners (Healthcare): CVC's healthcare practice invests across pharma, MedTech, and healthcare services. Notable prior exposure through Sebia (where ARCHIMED partner Adelus was CEO). Direct competitor to ARCHIMED for European healthcare buyouts.

Emerging players

• Ampersand Capital Partners: Ampersand is a PE firm exclusively focused on healthcare and life sciences, investing in pharma services, diagnostics, and life science tools. Comparable to ARCHIMED's smaller funds (MED Rise, MED II) in deal size and specialty orientation.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/archimed---investors-in-healthcare

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries21 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A4 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ARCHIMED